KPI data tables
BioNTech operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Cash and cash equivalents | Current security investments | Non-current security investments |
|---|---|---|---|
| Q3 2026 | 10.201 | 4.39 | 1.573 |
| Q2 2026 | 9.741 | 5.035 | 1.858 |
| Q1 2026 | 9.939 | 4.697 | 2.127 |
| Q4 2025 | 7.675 | 7.159 | 2.402 |
| Q3 2025 | 10.093 | 4.276 | 2.336 |
| Q2 2025 | 10.269 | 3.364 | 2.356 |
| Q1 2025 | 10.185 | 3.542 | 2.128 |
| Q4 2024 | 9.762 | 6.536 | 1.061 |
Source: BioNTech earnings releases and Form 6-K liquidity footnotes (CIK 0001776985). YE2024: Q4 2024 Exhibit 99.2 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm (€9,761.9 / €6,536.2 / €1,061.1 million). Q1 2025: 5 May 2025 earnings release https://investors.biontech.de/news-releases/news-release-details/biontech-announces-first-quarter-2025-financial-results-and (€10,184.9 / €3,542.0 / €2,127.5 million). Q2 2025: 4 Aug 2025 earnings release https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2025/08/biontech-announces-second-quarter-2025-financial-results-and.html (€10,269.5 / €3,363.8 / €2,356.0 million). Q3 2025: 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm (€10,092.9 / €4,275.6 / €2,336.4 million). YE2025: 10 Mar 2026 earnings release https://www.sec.gov/Archives/edgar/data/1776985/000177698526000016/a991bntxq4_pr.htm (€7,675.4 / €7,158.5 / €2,401.7 million). Q1 2026: 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000031/bntxq12026ex991quarterlyre.htm (€9,939.4 / €4,696.9 / €2,127.0 million). Q2 2026: 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm (€9,741.0 / €5,035.1 / €1,858.1 million). Q3 2026: 6-K Exhibit 99.1 filed 3 Nov 2026 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000081/bntxq32026ex991quarterlyre.htm (€10,200.8 / €4,390.2 / €1,572.8 million). Chart billions = printed millions / 1,000.
| Period | COVID-19 vaccine revenues (€M) |
|---|---|
| Q3 2026 | 554.3 |
| Q2 2026 | 51.9 |
| Q1 2026 | 66.9 |
| Q4 2025 | 855.7 |
| Q3 2025 | 853.3 |
| Q2 2025 | 153.3 |
| Q1 2025 | 133 |
| Q4 2024 | 1,122.1 |
| Q3 2024 | 1,113.9 |
| Q2 2024 | 71.9 |
| Q1 2024 | 124.2 |
Source: BioNTech Form 6-K and Form 20-F revenue notes (CIK 0001776985). Q2 2024 and H1 2024: 6-K Exhibit 99.1, three and six months ended 30 June 2025, https://www.sec.gov/Archives/edgar/data/1776985/000177698525000051/bnt_2025q2ex99x1quarterlyr.htm (€71.9 million and €196.1 million). Q3 2024 and 9M 2024: 6-K Exhibit 99.1, three and nine months ended 30 Sep 2025, https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm (€1,113.9 million and €1,310.0 million). FY2024: Form 20-F year ended 31 Dec 2025 Note 6.1, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/R13.htm (€2,432.1 million). Q1 2025: 6-K Exhibit 99.1, three months ended 31 Mar 2026, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000031/bntxq12026ex991quarterlyre.htm (€133.0 million). Q2 2025 and H1 2025 / Q2 2026 and H1 2026: 6-K Exhibit 99.1, three and six months ended 30 June 2026, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm (€153.3 million, €286.3 million, €51.9 million, €118.8 million). Q3 2025 and 9M 2025: same Q3 2025 6-K (€853.3 million and €1,139.6 million). FY2025: 20-F Note 6.1 (€1,995.3 million). Q1 2026: Q1 2026 6-K (€66.9 million). Q3 2026: 6-K Exhibit 99.1 filed 3 Nov 2026, three months ended 30 Sep 2026, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000081/bntxq32026ex991quarterlyre.htm (€554.3 million; nine months €673.2 million).
| Period | COVID-19 vaccine | Out-licensing (BMS pumitamig) | Other revenues |
|---|---|---|---|
| Q3 2026 | 554.3 | 683 | 51.9 |
| Q2 2026 | 51.9 | 0 | 53.7 |
| Q1 2026 | 66.9 | 0 | 51.2 |
| Q4 2025 | 855.7 | 0 | 51.7 |
| Q3 2025 | 853.3 | 613 | 52.6 |
| Q2 2025 | 153.3 | 0 | 107.5 |
| Q1 2025 | 133 | 0 | 49.8 |
| Q4 2024 | 1,122.1 | 0 | 67.9 |
| Q3 2024 | 1,113.9 | 0 | 130.9 |
| Q2 2024 | 71.9 | 0 | 56.8 |
| Q1 2024 | 124.2 | 0 | 63.4 |
Source: BioNTech Form 6-K revenue notes (CIK 0001776985). Q2 2025 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000051/bnt_2025q2ex99x1quarterlyr.htm (Q2 2024/2025 and H1). Q3 2025 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm (Q3 and 9M 2024/2025, including out-licensing €613.0 million). Form 20-F year ended 31 Dec 2025 Note 6.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/R13.htm (FY COVID-19 vaccine, out-licensing, other). Q1 2026 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000031/bntxq12026ex991quarterlyre.htm. Q2 2026 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm. Q3 2026 6-K Exhibit 99.1 filed 3 Nov 2026 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000081/bntxq32026ex991quarterlyre.htm (COVID-19 vaccine 554.3, out-licensing 683.0, other 51.9, total 1,289.2). Q4 2024 and Q4 2025 category amounts equal FY minus 9M from those filings.
| Period | Pfizer | German Federal Ministry of Health | Bristol Myers Squibb | Other customers |
|---|---|---|---|---|
| FY 2025 | 1,602 | 627.5 | 613 | 27.4 |
| FY 2024 | 2,011.7 | 701 | 0 | 38.4 |
| FY 2023 | 3,293 | 473.6 | 0 | 52.4 |
Source: BioNTech Form 20-F for the year ended 31 Dec 2025, Note 6.1 Revenues from Contracts with Customers, Revenues by customers table. SEC XBRL https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/R13.htm and HTML 20-F https://www.sec.gov/Archives/edgar/data/1776985/000177698526000023/bntx-20251231.htm (filed 10 Mar 2026, CIK 0001776985). FY2025: Pfizer €1,602.0 million, German Federal Ministry of Health €627.5 million, Bristol Myers Squibb €613.0 million, other customers €27.4 million. FY2024: €2,011.7 / €701.0 / dash / €38.4 million. FY2023: €3,293.0 / €473.6 / dash / €52.4 million. Dashes charted as 0.